Theralase Completes Ruvidar Phase II Bladder Cancer Study
The clinical trial evaluated a light-activated drug therapy for patients who are unresponsive to traditional BCG treatment.
Updated on Oct. 26, 2026 in Cancer
Live Poll
Do you trust emerging medical technologies to improve treatment outcomes for complex diseases?
Theralase Technologies has completed enrollment and gathered clinical data for its Phase II study of Ruvidar, a light-activated treatment for BCG-unresponsive bladder cancer. The study involved 96 patients across 11 clinical sites, with 87 participants completing the full trial.
Why it matters
This study aims to provide a new therapeutic option for patients with BCG-unresponsive bladder cancer, a condition with limited standard treatment alternatives. The findings offer potential for regulatory pathways in both Canada and the United States by 2027.
Of the 96 participants enrolled, 81% were aged 65 or older and 98% were BCG-unresponsive. The trial documented 25 serious adverse events, while common treatment-emergent issues included hematuria and urinary urgency.
The players
Theralase Technologies
A company headquartered in Toronto that develops light-activated drugs and medical laser systems for cancer and other medical applications.
The details
The treatment uses the Ruvidar drug activated by the company's TLC-3200 Medical Laser System, with participants followed for up to 3 years post-procedure. While 87 patients have completed the study, nine individuals are still pending assessment for secondary endpoints.
Timeline
October 26, 2026: Theralase released an update on clinical study results.
1Q2027: Expected completion of GLP toxicology studies for Rutherrin.
2027: Anticipated marketing decisions from health regulators.
2027: Planned commencement of clinical studies for HSV-1 cold sores.
The Big Picture
This study advances the clinical development of light-activated photodynamic therapies by moving a targeted, light-sensitive molecule from experimental trial toward potential standard regulatory approval.
Patients dealing with BCG-unresponsive bladder cancer may eventually gain access to a non-traditional, light-activated treatment protocol. This development could provide an alternative option for elderly populations who represent the majority of this patient demographic.
The takeaway
The successful completion of this Phase II study demonstrates the potential of combining specific drug compounds with laser technology to treat resistant cancer types. Patients should monitor future regulatory updates as the company moves toward potential international market submissions in 2027.
What happens next
Theralase plans to submit a New Drug Submission to Health Canada and a New Drug Application to the FDA in 2027, followed by an effort to secure global licensing agreements for the technology.
Further reading
Learn more about the latest research and advancements in the Cancer section.
More information
Read the detailed company regulatory filings regarding the study results.
Live Poll
Do you trust emerging medical technologies to improve treatment outcomes for complex diseases?
